A nurse-led intervention addressed completion of preinfusion lab tests, improving patient preparedness for infusion, multidisciplinary coordination, and patient outcomes.

USA News Group News Commentary - The recent FDA approval in November of the first bispecific antibody combination for second-line blood cancer treatment marks the departure from traditional ...

Patients should be selected for treatment with Enhertu in combination with pertuzumab based on confirmed HER2-positive status or HER2 gene amplification (IHC 3+ or ISH+).

CAR T-cell therapy has revolutionized the treatment of certain hematologic malignancies, providing durable remissions for patients who once had few options. Understandably, both patients and oncology ...